Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA – Get Free Report) hit a new 52-week high during trading on Monday . The company traded as high as $27.98 and last traded at $27.98, with a volume of 450 shares traded. The stock had previously closed at $27.44.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 target price for the company. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, Kiniksa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $33.60.
Check Out Our Latest Analysis on Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals Price Performance
Insider Buying and Selling at Kiniksa Pharmaceuticals
In other Kiniksa Pharmaceuticals news, insider John F. Paolini sold 60,692 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total value of $1,585,275.04. Following the completion of the transaction, the insider now owns 52,038 shares in the company, valued at $1,359,232.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, COO Eben Tessari sold 17,500 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $26.91, for a total transaction of $470,925.00. Following the completion of the sale, the chief operating officer now owns 119,911 shares in the company, valued at approximately $3,226,805.01. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John F. Paolini sold 60,692 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 112,692 shares of company stock worth $2,950,315 over the last 90 days. Corporate insiders own 54.57% of the company’s stock.
Institutional Investors Weigh In On Kiniksa Pharmaceuticals
Several hedge funds have recently made changes to their positions in KNSA. Hhlr Advisors LTD. acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $61,868,000. Millennium Management LLC boosted its stake in shares of Kiniksa Pharmaceuticals by 159.8% during the second quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after buying an additional 382,539 shares during the period. Rubric Capital Management LP boosted its stake in shares of Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after buying an additional 223,094 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Kiniksa Pharmaceuticals by 31.2% during the second quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after buying an additional 157,741 shares during the period. Finally, Hussman Strategic Advisors Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals during the first quarter worth about $3,107,000. Institutional investors and hedge funds own 53.95% of the company’s stock.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Featured Stories
- Five stocks we like better than Kiniksa Pharmaceuticals
- Consumer Staples Stocks, Explained
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- The Significance of Brokerage Rankings in Stock Selection
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.